Palmoplantar Pustulosis: A Systematic Review of Risk Factors and Therapies

被引：7
作者：
Heidemeyer, Kristine [1 ,2 ,5 ]
Lee, Marco May [3 ]
Cazzaniga, Simone [1 ,2 ]
Yawalkar, Nikhil [1 ]
Naldi, Luigi [2 ,4 ]
机构：
[1] Inselspital Univ, Hosp Bern, Dept Dermatol, Bern, Switzerland
[2] Ctr Studi GISED, Bergamo, Italy
[3] Univ Parma, Sect Dermatol, Dept Clin & Expt Med, Parma, Italy
[4] S Bortolo Hosp, Dermatol Dept, Vicenza, Italy
[5] Inselspital Univ, Hosp Bern, Dept Dermatol, Freiburgstr 34, CH-3010 Bern, Switzerland
来源：
PSORIASIS-TARGETS AND THERAPY | 2023年 / 13卷
关键词：
palmoplantar; pustulosis; psoriasis; treatment; risk factors; DOUBLE-BLIND; CLINICAL-FEATURES; ORAL ALITRETINOIN; CONTROLLED TRIAL; EXCIMER LIGHT; TOPICAL PUVA; RAY THERAPY; PLUS UVA; PSORIASIS; EFFICACY;
D O I：
10.2147/PTT.S400402
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Palmoplantar pustulosis (PPP) is a chronic, relapsing, inflammatory disease that can occur alone or in association with arthritis. There is still controversy about whether it should be separated from psoriasis or classified as pustular psoriasis. Furthermore, drug-induced paradoxical PPP is a special variant of PPP that differs from classic PPP in several ways. Treatment of PPP is still challenging, and there are a number of treatment-resistant cases. This review summarizes the risk factors for the development of PPP and the currently available treatment modalities. Female sex, smokers or ex-smokers, obesity, thyroid dysfunction, and treatment with a tumor necrosis factor (TNF)-alpha inhibitor have been identified as risk factors for the disease's development, severity, and course. Topical treatments and phototherapy are effective for some patients and are used as a first-line or adjuvant treatment modality. Conventional treatments including retinoids and fumaric acid show good effects and can increase the efficacy of treatment with psoralen + ultraviolet light therapy (PUVA). Ciclosporin is fast acting, but relapse mostly occurs immediately after cessation. TNF-alpha inhibitors are efficient, and an even better response can be achieved with IL-17 and IL-23 blockers as well as apremilast. The effect of Janus kinase inhibitors seems to be promising according to case reports, but further investigations with larger cohorts are needed.
引用
收藏
页码：33 / 58
页数：26
相关论文
共 137 条
  • [11] Bissonnette R, 2008, J Drugs Dermatol, V7, P940
  • [12] A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
    Bissonnette, Robert
    Maari, Catherine
    Tsianakas, Athanasios
    Reid, DeAnne
    McCutchan, Sara
    Baumgartner, Scott
    Mackay, James
    Bhakta, Nihar
    [J]. DERMATOLOGY AND THERAPY, 2021, 11 (06) : 2179 - 2193
  • [13] Brunasso Alexandra Maria Giovanna, 2021, Fac Rev, V10, P62, DOI 10.12703/r/10-62
  • [14] Ustekinumab in the treatment of palmoplantar pustular psoriasis - a case series of nine patients
    Buder, Valeska
    Herberger, Katharina
    Jacobi, Arnd
    Augustin, Matthias
    Radtke, Marc Alexander
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 (11):
  • [15] Open label trial of alefacept in palmoplantar pustular psoriasis
    Carr, David
    Tusa, Mark G.
    Carroll, Christie L.
    Pearce, Daniel J.
    Camacho, Fabian
    Kaur, Mandeep
    Cook, Christina
    Willard, Joy
    Mccarty, Ann
    Fleischer, Alan B., Jr.
    Liu, Clive M.
    Goffe, Bernard S.
    Feldman, Steven R.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2008, 19 (02) : 97 - 100
  • [16] clinicaltrials, Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
  • [17] Identifier, NCT04451720
  • [18] clinicaltrials, Deucravacitinib for the Treatment of Palmoplantar Pustulosis
  • [19] Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)
    Cro, S.
    Cornelius, V. R.
    Pink, A. E.
    Wilson, R.
    Pushpa-Rajah, A.
    Patel, P.
    Abdul-Wahab, A.
    August, S.
    Azad, J.
    Becher, G.
    Chapman, A.
    Dunnil, G.
    Ferguson, A. D.
    Fogo, A.
    Ghaffar, S. A.
    Ingram, J. R.
    Kavakleiva, S.
    Ladoyanni, E.
    Leman, J. A.
    Macbeth, A. E.
    Makrygeoegou, A.
    Parslew, R.
    Ryan, A. J.
    Sharma, A.
    Shipman, A. R.
    Sinclair, C.
    Wachsmuth, R.
    Woolf, R. T.
    Wright, A.
    McAteer, H.
    Barker, J. N. W. N.
    Burden, A. D.
    Griffiths, C. E. M.
    Reynolds, N. J.
    Warren, R. B.
    Lachmann, H. J.
    Capon, F.
    Smith, C. H.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (02) : 245 - 256
  • [20] Cro S, Efficacy and Mechanism Evaluation. The Interleukin 1 Receptor Antagonist Anakinra to Reduce Disease Severity of Palmoplantar Pustulosis in Adults: APRICOT RCT and PLUM Mechanistic Study
12345678910